Featuring perspectives from Dr Natalie S Callander and Dr Thomas Martin, including the following topics:

• Introduction (0:00)
• Current and Emerging Therapeutic Approaches for Multiple Myeloma — Dr Callander (4:42)
• CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Martin (31:16)

CME information and select publications

Featuring perspectives from Dr Farshid Dayyani, Ms Caroline Kuhlman, Dr Philip A Philip and Ms Amanda K Wagner, including the following topics:

• Introduction: Initial Management of Pancreatic Adenocarcinoma (PAD) (0:00)
• Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD (19:01)
• Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (54:38)
• Importance of Palliative Care for Advanced PAD (1:06:09)
• Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD (1:14:59)
• Promising Investigational Strategies for PAD (1:26:56)

NCPD information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics:

• Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00)
• Sequencing bispecific antibodies and CAR T-cell therapy (10:40)
• Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03)
• Optimizing maintenance therapy for patients with MM (31:11)
• Novel management strategies for smoldering myeloma (36:29)
• Role of anti-CD38 antibodies in the up-front management of MM (41:41)
• Available data with cereblon E3 ligase modulatory drugs for MM (47:45)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics:

• Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00)
• Updated data with belantamab mafodotin for the management of MM (12:39)
• Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52)
• ASH 2024 updates with other novel agents and strategies for the management of MM (21:32)

CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

• Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
  • Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract 
• Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
  • Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract 
  • Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05. 
• Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
  • VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P. 
• Selective review of trials of oral SERDs in the adjuvant setting (11:27)
  • A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, MD, including the following topics:

• Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Janjigian (0:00)
• Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers — Dr Klempner(28:38)

CME information and select publications

Featuring an interview with Dr Lindsey Roeker, including the following topics:

• Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
• Safety of BTK inhibitors in older and frail patients with CLL (3:41)
• Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
• Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
• Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
• Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
• Sequencing, tolerability and future development involving pirtobrutinib (25:57)
• Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
• Clinical considerations in the management of Richter's transformation (38:14)
• Survival outcomes and quality of life for patients with CLL (41:02)
• Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:

• Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
• Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03)
• Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
• Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
• Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52)
• Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
• Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38)
• Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15)
• Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
• Available data with epcoritamab monotherapy for R/R CLL (26:58)
• The emerging pharmacologic class of BTK degraders (29:04)

CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

• EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00)
• Bruton Tyrosine Kinase Inhibitors for FL (5:43)
• Anti-CD19 Antibodies for FL (9:40)
• Other Novel Agents Under Clinical Development for FL (18:50)
• Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06)
• Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07)
• Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46)

CME information and select publications

Featuring perspectives from Dr Shilpa Gupta and Dr Jonathan E Rosenberg, including the following topics:

• Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta (0:00)
• Optimizing the Treatment of Metastatic UBC — Dr Rosenberg (21:52)

CME information and select publications